Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208722
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nadal, Ernest | - |
dc.contributor.author | Rodríguez Abreu, Delvys | - |
dc.contributor.author | Simó, Marta | - |
dc.contributor.author | Massutí, Bartomeu | - |
dc.contributor.author | Juan, Oscar | - |
dc.contributor.author | Huidobro, Gerardo | - |
dc.contributor.author | López, Rafael | - |
dc.contributor.author | Castro, Javier de | - |
dc.contributor.author | Estival, Anna | - |
dc.contributor.author | Mosquera, Joaquín | - |
dc.contributor.author | Sullivan, Ivana | - |
dc.contributor.author | Felip, Enriqueta | - |
dc.contributor.author | Blasco, Ana | - |
dc.contributor.author | Guirado, Maria | - |
dc.contributor.author | Pereira, Eva | - |
dc.contributor.author | Vilariño, Noelia | - |
dc.contributor.author | Navarro, Valentín | - |
dc.contributor.author | Bruna, Jordi | - |
dc.date.accessioned | 2024-03-13T11:09:40Z | - |
dc.date.available | 2024-03-13T11:09:40Z | - |
dc.date.issued | 2023-10-01 | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | http://hdl.handle.net/2445/208722 | - |
dc.description.abstract | PURPOSEThe Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials.METHODSThis single-arm phase II clinical trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed was given for four to six cycles followed by atezolizumab plus pemetrexed until progression for a maximum of 2 years. The primary end points were to determine the progression-free survival (PFS) rate at 12 weeks and the incidence of grade >= 3 adverse events during the first 9 weeks. Intracranial outcomes were assessed using response assessment in neuro-oncology brain metastases criteria.RESULTSForty patients were enrolled and 22 (55%) were receiving corticosteroids at baseline. The overall 12-week PFS rate was 62.2% (95% credibility interval [CrI], 47.1 to 76.2). The rate of grade 3/4 adverse events during the first 9 weeks was 27.5%. Most neurologic events were grade 1 and 2 but five patients (12.5%) experienced grade 3-4 neurologic events. With a median follow-up of 31 months, intracranial median PFS was 6.9 months and response rate was 42.7% (95% CrI, 28.1 to 57.9). Systemic median PFS was 8.9 months and response rate was 45% (95% CrI, 28.1 to 57.9). The median overall survival (OS) was 11.8 months (95% CI, 7.6 to 16.9) and the 2-year OS rate was 27.5% (95% CI, 16.6 to 45.5).CONCLUSIONAtezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society of Clinical Oncology (ASCO) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1200/JCO.22.02561 | - |
dc.relation.ispartof | Journal of Clinical Oncology, 2023, vol. 41, num. 28, p. 4478-4485 | - |
dc.relation.uri | https://doi.org/10.1200/JCO.22.02561 | - |
dc.rights | cc by-nc-nd (c) American Society of Clinical Oncology (ASCO), 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Tumors cerebrals | - |
dc.subject.classification | Càncer de pulmó | - |
dc.subject.other | Brain tumors | - |
dc.subject.other | Lung cancer | - |
dc.title | Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-11-28T09:31:27Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37603816 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
nadal-et-al-2023-phase-ii-trial-of-atezolizumab-combined.pdf | 778.44 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License